Maria E. Arcila

Overview

Best Publications

• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

  Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  2987
  Citations

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

  2920
  Citations

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  2525
  Citations

• Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

  Donavan T. Cheng;Talia N. Mitchell;Ahmet Zehir;Ronak H. Shah

  2291
  Citations

• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  Neal I. Lindeman;Philip T. Cagle;Dara L. Aisner;Maria E. Arcila

  1623
  Citations

• Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

  Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  1489
  Citations

• Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

  Zhenfeng Zhang;Zhenfeng Zhang;Jae Cheol Lee;Luping Lin;Victor Olivas

  1302
  Citations

• Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

  Paul K. Paik;Maria E. Arcila;Michael Fara;Camelia S. Sima

  765
  Citations

• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  Ken Takezawa;Valentina Pirazzoli;Maria E. Arcila;Caroline A. Nebhan

  750
  Citations

• Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

  Catherine C. Coombs;Ahmet Zehir;Sean M. Devlin;Ashwin Kishtagari

  703
  Citations

• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

  Geoffrey R. Oxnard;Maria E. Arcila;Camelia S. Sima;Gregory J. Riely

  698
  Citations

• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  Maria E. Arcila;Geoffrey R. Oxnard;Khedoudja Nafa;Gregory J. Riely

  687
  Citations

• Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  Lawrence J. Jennings;Maria E. Arcila;Christopher Corless;Suzanne Kamel-Reid;Suzanne Kamel-Reid

  675
  Citations

• ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

  Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  630
  Citations

• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  Juliann Chmielecki;Jasmine Y Foo;Geoffrey R. Oxnard;Katherine Hutchinson

  612
  Citations

• Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

  Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron

  585
  Citations

• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.

  Hiroyuki Yasuda;Eunyoung Park;Cai Hong Yun;Natasha J. Sng

  540
  Citations

• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  Kadoaki Ohashi;Lecia V. Sequist;Maria E. Arcila;Teresa Moran

  508
  Citations

• Cancer therapy shapes the fitness landscape of clonal hematopoiesis

  Kelly L. Bolton;Ryan N. Ptashkin;Teng Gao;Lior Braunstein

  504
  Citations

• Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

  Wassim Abida;Joshua Armenia;Anuradha Gopalan;Ryan Brennan

  495
  Citations